{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T03:30:37Z","timestamp":1785295837672,"version":"3.55.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["NCT04774094"],"award-info":[{"award-number":["NCT04774094"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jgar.2025.03.001","type":"journal-article","created":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T18:23:23Z","timestamp":1741458203000},"page":"248-255","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Effectiveness and safety of ceftazidime-avibactam in Chinese patients with hospital-acquired pneumonia, including ventilator-associated pneumonia: A Phase 4, multi-centre, open-label study"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1108-3994","authenticated-orcid":false,"given":"Jinyi","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3803-5877","authenticated-orcid":false,"given":"Haihui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"NanYan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyue","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuke","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiqing","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangfa","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunsong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panpan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paurus","family":"Irani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rienk","family":"Pypstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junchao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanglei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4952-056X","authenticated-orcid":false,"given":"Yuting","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2025.03.001_bib0001","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.21037\/jtd.2019.06.09","article-title":"Chinese guidelines for the diagnosis and treatment of hospital-acquired pneumonia and ventilator-associated pneumonia in adults (2018 Edition)","volume":"11","author":"Shi","year":"2019","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.jgar.2025.03.001_bib0002","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s10096-020-04046-9","article-title":"Clinical and microbiological characteristics of adults with hospital-acquired pneumonia: a 10-year prospective observational study in China","volume":"40","author":"Yin","year":"2021","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2025.03.001_bib0003","doi-asserted-by":"crossref","first-page":"S153","DOI":"10.1093\/cid\/ciy692","article-title":"The current epidemiological landscape of ventilator-associated pneumonia in the intensive care unit: a multicenter prospective observational study in China","volume":"67","author":"Xie","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2025.03.001_bib0004","doi-asserted-by":"crossref","first-page":"373s","DOI":"10.1378\/chest.119.2_suppl.373S","article-title":"Hospital-acquired pneumonia: risk factors, microbiology, and treatment","volume":"119","author":"Lynch","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.jgar.2025.03.001_bib0005","doi-asserted-by":"crossref","first-page":"e00047-19","DOI":"10.1128\/CMR.00047-19","article-title":"Epidemiology of beta-lactamase-producing pathogens","volume":"33","author":"Bush","year":"2020","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jgar.2025.03.001_bib0006","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/s41579-020-0340-0","article-title":"Critical analysis of antibacterial agents in clinical development","volume":"18","author":"Theuretzbacher","year":"2020","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.jgar.2025.03.001_bib0007","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2025.03.001_bib0008","doi-asserted-by":"crossref","first-page":"1700582","DOI":"10.1183\/13993003.00582-2017","volume":"50","author":"Torres","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jgar.2025.03.001_bib0009","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/cid\/ciw133","article-title":"Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program","volume":"62","author":"Mazuski","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2025.03.001_bib0010","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ijantimicag.2017.01.010","article-title":"A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime\/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia","volume":"49","author":"Qin","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2025.03.001_bib0011","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","volume":"16","author":"Carmeli","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2025.03.001_bib0012","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/cid\/ciw378","article-title":"Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program","volume":"63","author":"Wagenlehner","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2025.03.001_bib0013","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","article-title":"Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial","volume":"18","author":"Torres","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2025.03.001_bib0014","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1093\/jac\/dkad280","article-title":"Efficacy and safety of ceftazidime\/avibactam in patients with infections caused by \u03b2-lactamase-producing Gram-negative pathogens: a pooled analysis from the phase 3 clinical trial programme","volume":"78","author":"Torres","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2025.03.001_bib0015","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1093\/jac\/dky204","article-title":"Clinical activity of ceftazidime\/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime\/avibactam Phase III clinical trial programme","volume":"73","author":"Stone","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2025.03.001_bib0016","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1007\/s40121-021-00507-6","article-title":"Ceftazidime-avibactam for the treatment of serious Gram-negative infections with limited treatment options: a systematic literature review","volume":"10","author":"Soriano","year":"2021","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.jgar.2025.03.001_bib0017","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s40121-023-00762-9","article-title":"The use and effectiveness of ceftazidime-avibactam in real-world clinical practice: EZTEAM study","volume":"12","author":"Soriano","year":"2023","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.jgar.2025.03.001_bib0018","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jiph.2022.02.003","article-title":"Analysis of the clinical application of ceftazidime-avibactam in China","volume":"15","author":"Wang","year":"2022","journal-title":"J Infect Public Health"},{"key":"10.1016\/j.jgar.2025.03.001_bib0019","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1007\/s40121-024-00999-y","article-title":"Ceftazidime-avibactam in the treatment of patients with bacteremia or nosocomial pneumonia: a systematic review and meta-analysis","volume":"13","author":"Shields","year":"2024","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.jgar.2025.03.001_bib0020","unstructured":"Pfizer. Summary of product characteristics: Zavicefta 2 g\/0.5 g powder for concentrate for solution for infusion; 2024. Available from: https:\/\/www.ema.europa.eu\/documents\/product-information\/zavicefta-epar-product-information_en.pdf. [Accessed 05 March 2024]."},{"key":"10.1016\/j.jgar.2025.03.001_bib0021","unstructured":"AbbVie. Full prescribing information: AVYCAZ\u00ae (ceftazidime and avibactam) for injection, for intravenous use; 2024. Available from: https:\/\/www.rxabbvie.com\/pdf\/avycaz_pi.pdf. [Accessed 11 March 2024]."},{"key":"10.1016\/j.jgar.2025.03.001_bib0022","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1214\/ss\/1009213286","article-title":"Interval estimation for a binomial proportion","volume":"16","author":"Brown","year":"2001","journal-title":"Statist Sci"},{"key":"10.1016\/j.jgar.2025.03.001_bib0023","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jspi.2004.01.005","article-title":"One-sided confidence intervals in discrete distributions","volume":"131","author":"Cai","year":"2005","journal-title":"J Stat Plan Inference"},{"key":"10.1016\/j.jgar.2025.03.001_bib0024","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0023-2020","article-title":"Is ventilated hospital-acquired pneumonia a worse entity than ventilator-associated pneumonia?","volume":"29","author":"Vallecoccia","year":"2020","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.jgar.2025.03.001_bib0025","first-page":"325","article-title":"Epidemiology of ICU-acquired pneumonia","volume":"24","author":"Ferrer","year":"2018","journal-title":"Curr Opin Crit Care"},{"key":"10.1016\/j.jgar.2025.03.001_bib0026","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s40264-020-00934-3","article-title":"Safety profile of ceftazidime-avibactam: pooled data from the adult phase II and phase III clinical trial programme","volume":"43","author":"Cheng","year":"2020","journal-title":"Drug Saf"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221371652500061X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221371652500061X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T13:59:47Z","timestamp":1762610387000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221371652500061X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":26,"alternative-id":["S221371652500061X"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2025.03.001","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness and safety of ceftazidime-avibactam in Chinese patients with hospital-acquired pneumonia, including ventilator-associated pneumonia: A Phase 4, multi-centre, open-label study","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2025.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}